scholarly journals 287O Risen from ashes- A prospective observational study of poor prognostic multiple myeloma patients with paraplegia/ paraparesis

2015 ◽  
Vol 26 ◽  
pp. ix85
Author(s):  
A.S. Anand ◽  
V.G. Kuriakose ◽  
K.P. Resmi ◽  
P.S. Sabarinath
2020 ◽  
Vol 63 (5) ◽  
pp. 211
Author(s):  
Po-Nan Wang ◽  
Chieh-LinJerry Teng ◽  
Tran-Der Tan ◽  
Ying-Chung Hong ◽  
Sin-Syue Li ◽  
...  

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e19531-e19531
Author(s):  
Dipanjan Panda ◽  
Atul Sharma ◽  
Vinod Raina ◽  
Lalit Kumar ◽  
Renu Saxena ◽  
...  

e19531 Background: Venous thromboembolism (VTE) is a major complication of Multiple myeloma. The exact cause of thrombosis, role of anti myeloma drugs especially immunomodulators and steroids and the relation of thrombosis with alteration of thrombotic profile is not clear. While some available data is suggestive of low incidence of VTE in Asian population, true incidence and risk factors of VTE in Indian population is not known.So the present study was undertaken to have an evaluation of prothrombotic factors in Indian population. Methods: A prospective observational study was conducted from July 2008 to November 2009 at All India Institute of Medical Sciences (AIIMS), New Delhi, India. Thirty patients of newly diagnosed myeloma were recruited and were treated with thalidomide and dexamethasone for 4 months. Prothrombotic profile including protein Cand S, activated protein C resistance, plasma fibrinogen, factor VII and von Willebrand factor level was measured and Doppler study was done at baseline and after 4 months. Statistical analysis was done using SPSS 15 software. Frequency distribution, mean, median, range, standard deviation, Inter Quartile Range were calculated. To find out difference between pre and post treatment, Macnemar chi-square test (for proportion) and paired t test (mean) were done. Results: At the base line 4 patients (13%) had low protein C, 3 (10 %) had low protein S and 2 patients (6%) had high factor VIII. Post induction therapy 7 patients showed low protein C, 1 had low protein S and 1 had high factor VIII value. Rest of the factors was within normal limit both at baseline and post treatment in other patients. During the study period 2 subjects developed DVT. While one had low protein S, other patient had low protein C and low anti thrombin III which was done to find out the cause of DVT. Conclusions: Incidence of DVT in our patients seems to be less than western published data. Although thrombotic factors abnormalities are present in myeloma patients but the relation of coagulation factor abnormalities and development of DVT require further study. A larger prospective trial may be required to get a clear picture.


Sign in / Sign up

Export Citation Format

Share Document